NCT06189820 Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases
| NCT ID | NCT06189820 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Erasme University Hospital |
| Condition | Pulmonary Fibrosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2023-03-09 |
| Primary Completion | 2027-03-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 70 participants in total. It began in 2023-03-09 with a primary completion date of 2027-03-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET/CT.
Eligibility Criteria
Inclusion Criteria: * Adults patients with a fibrotic lung disease (idiopathic pulmonary fibrosis (IPF) or non-IPF fibrotic ILD) as defined according to the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guidelines Exclusion Criteria: * Pregnant or nursing patients * Patients with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study. * Patients with an active lung neoplasm or any active neoplasm for blood samples
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06189820 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pulmonary Fibrosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06189820 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06189820 currently recruiting?
Yes, NCT06189820 is actively recruiting participants. Contact the research team at benjamin.bondue@hubruxelles.be for enrollment information.
Where is the NCT06189820 trial being conducted?
This trial is being conducted at Brussels, Belgium.
Who is sponsoring the NCT06189820 clinical trial?
NCT06189820 is sponsored by Erasme University Hospital. The trial plans to enroll 70 participants.